Ketolides: An emerging treatment for macrolide-resistant respiratory infections, focusing on S. pneumoniae

Expert Opinion on Emerging Drugs

Volumn 8, Issue 2, 2003, Pages 297-321

  Zhanel, George G ^a,b   Hisanaga, Tamiko ^b   Nichol, Kim ^a   Wierzbowski, Aleksandra ^b   Hoban, Daryl J ^a,b  

^a HEALTH SCIENCES CENTRE   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Cethromycin (ABT 773); Ketolides; Macrolide resistance; Telithromycin

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CARBAMAZEPINE; CEFUROXIME; CEFUROXIME AXETIL; CETHROMYCIN; CLARITHROMYCIN; DIGOXIN; ERYTHROMYCIN; HMR 3562; HMR 3787; ITRACONAZOLE; JNJ 17155437; JNJ 17155528; KETOCONAZOLE; KETOLIDE; LEVOFLOXACIN; MACROLIDE; PENICILLIN G; PENICILLIN V; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RANITIDINE; SUCRALFATE; TE 802; TELITHROMYCIN; THEOPHYLLINE DERIVATIVE; TROVAFLOXACIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; WARFARIN;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; CLINICAL TRIAL; CROSS RESISTANCE; DIARRHEA; DRUG BLOOD LEVEL; DRUG DESIGN; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG UPTAKE; FOOD DRUG INTERACTION; GASTROINTESTINAL SYMPTOM; GENE MUTATION; HUMAN; IC 50; LIVER TOXICITY; MINIMUM INHIBITORY CONCENTRATION; NAUSEA; NONHUMAN; PATHOGENESIS; RESPIRATORY TRACT INFECTION; REVIEW; RIBOSOME; SIDE EFFECT; STREPTOCOCCUS PNEUMONIAE; STRUCTURE ACTIVITY RELATION; VOMITING;

ANTI-BACTERIAL AGENTS; CLINICAL TRIALS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ERYTHROMYCIN; HUMANS; KETOLIDES; MACROLIDES; RESPIRATORY TRACT INFECTIONS; STREPTOCOCCUS PNEUMONIAE;

EID: 0346367066     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.8.2.297     Document Type: Review

References (184)

1. NICOLAU DP: Clinical and economic implications of antimicrobial resistance for the management of community-acquired respiratory tract infections. J. Antimicrob. Chemother. (2002) 50:61-70.
2. ZHANEL GG, DUECK M, HOBAN DJ et al.: Review of macrolides and ketolides: focus on respiratory tract infections. Drugs (2001) 61:443-498.
3. SCHLUNZEN F, HARMS JM, FRANCESCHI F et al.: Structural basis for the antibiotic activity of ketolides and azalides. Structure (Camb.) (2003) 11:329-338.
4. FILE TM JR, TAN JS: International guidelines for the treatment of community-acquired pneumonia in adults: the role of macrolides. Drugs (2003) 63:181-205.
5. AMSDEN GW: Erythromycin, clarithromycin and azithromycin: are the differences real? Clin. Ther. (1996) 18:56-72; discussion 55.
6. BLONDEAU JM, DECAROLIS E, METZLER KL, HANSEN GT: The macrolides. Expert Opin. Investig. Drugs (2002) 11:189-215.
7. WU YJ: Highlights of semisynthetic developments from erythromycin A. Curr. Pharm. Des. (2000) 6:181-223.
8. PISCITELLI SC, DANZIGER LH, RODVOLD FA: Clarithromycin and azithromycin: new macrolide antibiotics. Clin. Pharm. (1992) 11:137-152.
9. KOHNO Y, YOSHIDA H, SUWA T, SUGA T: Uptake of clarithromycin by rat lung cells, J. Antimicrob. Chemother. (1990) 26:503-513.
10. KOHNO Y, YOSHIDA H, SUWA T, SUGA T: Comparative pharmacokinetics of clarithromycin (TE-031), a new macrolide antibiotic and erythromycin in rats. Antimicrob. Agents Chemother. (1989) 33:751-756.
11. TINEL M, DESCATOIRE V, LARREY D et al.: Effects of clarithromycin on cytochrome P450. Comparison with other macrolides. J. Pharmacol. Exp. Ther. (1989) 250:746-751.
12. VON ROSENSTEIL NA, ADAM D: Macrolide antibacterials. Drug interactions of clinical significance. Drug Saf. (1995) 13:105-122.
13. AMSDEN GW: Advanced-generation macrolides: tissue-directed antibiotics. Int. J. Antimicrob. Agents (2001) 18(Suppl. 1):S11-S15.
14. DOERN GV, HEILMANN KP, HUYNH HK, RHOMBERG PR, COFFMAN SL, BRUEGGEMANN AB: Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999-2000, including a comparison of resistance rates since 1994-1995. Antimicrob. Agents Chemother. (2001) 45:1721-1729.
15. FELMINGHAM D, REINERT RR, HIRAKATA Y, RODLOFF A: Increasing prevalence of antimicrobial resistance among isolates of Streptococcus pneumoniae from the PROTEKT surveillance study and comparative in vitro activity of the ketolide, telithromycin. J. Antimicrob. Chemother. (2002) 50(Suppl. 51):25-37.
16. ZHANEL GG, PALATNICK L, NICHOL KA, BELLYOU T, LOW DE, HOBAN DJ: Antimicrobial resistance in respiratory tract Streptococcus pneumoniae isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002. Antimicrob. Agents Chemother. (2003) 47:1867-1874.
17. BARRY AL, FUCHS PC, BROWN SD: Relative potency of telithromycin, azithromycin and erythromycin against recent clinical isolates of Gram-positive cocci. Eur. J. Clin. Microbiol. Infect. Dis. (2001) 20:494-497.
18. SCHULIN T, WENNERSTEN CB, MOELLERING RC JR, ELIOPOULOS GM: In vitro activity of the new ketolide antibiotic HMR 3647 against Gram-positive bacteria. J. Antimicrob. Chemother. (1998) 42:297-301.
19. MASON EO JR, LAMBERTH LB, WALD ER, BRADLEY JS, BARSON WJ, KAPLAN SL: In vitro activities of cethromycin (ABT-773), a new ketolide, against Streptococcus pneumoniae strains that are not susceptible to penicillin or macrolides. Antimicrob. Agents Chemother. (2003) 47:166-169.
20. HAMILTON-MILLER JM, SHAH S: Patterns of phenotypic resistance to the macrolide-lincosamide-ketolide-streptogramin group of antibiotics in staphylococci. J. Antimicrob. Chemother. (2000) 46:941-949.
21. BARRY AL, FUCHS PC, BROWN SD: Antipneumococcal activities of a ketolide (HMR 3647), a streptogramin (quinupristin-dalfopristin), a macrolide (erythromycin) and a lincosamide (clindamycin). Antimicrob. Agents Chemother. (1998) 42:945-946.
22. JALAVA J, KATAJA J, SEPPALA H, HUOVINEN P: In vitro activities of the novel ketolide telithromycin (HMR 3647) against erythromycin-resistant Streptococcus species. Antimicrob. Agents Chemother. (2001) 45:789-793.
23. FELMINGHAM D: Evolving resistance patterns in community-acquired respiratory tract pathogens: first results from the PROTEKT global surveillance study. Prospective Resistant Organism Tracking and Epidemiology for the Ketolide Telithromycin. J. Infect. (2002) 44(Suppl. A):3-10.
24. PANKUCH GA, VISALLI MA, JACOBS MR, APPELBAUM PC: Susceptibilities of penicillin- and erythromycin-susceptible and -resistant pneumococci to HMR 3647 (RU 66647), a new kerolide, compared with susceptibilities to 17 other agents. Antimicrob. Agents Chemother. (1998) 42:624-630.
25. NAGAI K, APPELBAUM PC, DAVIES TA et al.: Susceptibilities to telithromycin and six other agents and prevalence of macrolide resistance due to L4 ribosomal protein mutation among 992 Pneumococci from 10 central and Eastern European countries. Antimicrob. Agents Chemother. (2002) 46:371-377.
26. SHORTRIDGE VD, ZHONG P, CAO Z et al.: Comparison of in vitro activities of ABT-773 and telithromycin against macrolide-susceptible and -resistant streptococci and staphylococci. Antimicrob. Agents Chemother. (2002) 46:783-786.
27. SCHMITZ FJ, SCHWARZ S, MILATOVIC D, VERHOEF J, FLUIT AC: In vitro activities of the ketolides ABT-773 and telithromycin and of three macrolides against genetically characterized isolates of Streptococcus pneumoniae, Streptococcus pyogenes, Haemophilus influenzae and Moraxella catarrhalis. J. Antimicrob. Chemother. (2002) 50:145-148.
28. HOBAN DJ, ZHANEL GG, KARLOWSKY JA: In vitro activity of the novel ketolide HMR 3647 and comparative oral antibiotics against Canadian respiratory tract isolates of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis. Diagn. Microbiol. Infect. Dis. (1999) 35:37-44.
29. WOOTTON M, BOWKER KE, JANOWSKA A, HOLT HA, MACGOWAN AP: In vitro activity of HMR 3647 against Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis and beta-haemolytic streptococci. J. Antimicrob. Chemother. (1999) 44:445-453.
30. OKAMOTO H, MIYAZAKI S, TATEDA K, ISHII Y, YAMAGUCHI K: Comparative in vitro activity of telithromycin (HMR 3647), three macrolides, amoxycillin, cefdinir and levofloxacin against Gram-positive clinical isolates in Japan. J. Antimicrob. Chemother. (2000) 46:797-802.
31. GIOVANETTI E, MONTANARI MP, MARCHETTI F, VARALDO PE: In vitro activity of ketolides telithromycin and HMR 3004 against italian isolates of Streptococcus pyogenes and Streptococcus pneumoniae with different erythromycin susceptibility. J. Antimicrob. Chemother. (2000) 46:905-908.
32. FARRELL DJ, MORRISSEY I, BAKKER S, FELMINGHAM D: Molecular characterization of macrolide resistance mechanisms among Streptococcus pneumoniae and Streptococcus pyogenes isolated from the PROTEKT 1999-2000 study. J. Antimicrob. Chemother. (2002) 50(Suppl. S1):39-47.
33. DESCHEEMAEKER P, CHAPELLE S, LAMMENS C et al.: Macrolide resistance and erythromycin resistance determinants among Belgian Streptococcus pyogenes and Streptococcus pneumaniae isolates. J. Antimicrob. Chemother. (2000) 45:167-173.
34. BARRY AL, FUCHS PC, BROWN SD: In vitro activity of the ketolide ABT-773. Antimicrob. Agents Chemother. (2001) 45:2922-2924.
35. BARRY AL, FUCHS PC, BROWN SD: In vitro activities of the ketolide HMR 3647 against recent Gram-positive clinical isolates and Haemophilus influenzae. Antimicrob. Agents Chemother. (1998) 42:2138-2140.
36. FARRELL DJ, DOUTHWAITE S, MORRISSEY I et al.: Macrolide resistance by ribosomal mutation in clinical isolates of Streptococcus pneumoniae from the PROTEKT 1999-2000 study. Antimicrob. Agents Chemother. (2003) 47:1777-1783.
37. BRUEGGEMANN AB, DOERN GV, HUYNH HK, WINGERT EM, RHOMBERG PR: In vitro activity of ABT-773, a new ketolide, against recent clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis. Antimicrob. Agents Chemother. (2000) 44:447-449.
38. DUBOIS J, ST-PIERRE C: In vitro activity of ABT-773 versus macrolides and quinolones against resistant respiratory tract pathogens. Diagn. Microbiol. Infect. Dis. (2001) 40:35-40.
39. SHORTRIDGE V, RAMER NC, MCDANIEL D, JOHNSON P, FLAMM RK: Study of the time kill kinetics and post antibiotic effect of ABT-773 with macrolide susceptible and resistant respiratory pathogens (abstract no. 2137). 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sept 17-20; Toronto, Canada (2000).
40. BAN N, NISSEN P, HANSEN J, MOORE PB, STEITZ TA: The complete atomic structure of the large ribosomal subunit at 2.4 A resolution. Science (2000) 289:905-920.
41. NISSEN P, HANSEN J, BAN N, MOORE PB, STEITZ TA: The structural basis of ribosome activity in peptide bond synthesis. Science (2000) 289:920-930.
42. POULSEN SM, KOFOED C, VESTER B: Inhibition of the ribosomal peptidyl transferase reaction by the mycarose moiety of the antibiotics carbomycin, spiramycin and tylosin. J. Mol. Biol. (2000) 304:471-481.
43. DOUTHWAITE S, HANSEN LH, MAUVAIS P: Macrolide-ketolide inhibition of MLS-resistant ribosomes is improved by alternative drug interaction with domain II of 23S rRNA. Mol. Microbiol. (2000) 36:183-193.
44. VESTER B, DOUTHWAITE S: Macrolide resistance conferred by base substitutions in 23S rRNA. Antimicrob. Agents Chemother. (2001) 45:1-12.
45. XIONG L, SHAH S, MAUVAIS P, MANKIN AS: A ketolide resistance mutation in domain II of 23S rRNA reveals the proximity of hairpin 35 to the peptidyl transferase centre. Mol. Microbiol. (1999) 31:633-639.
46. SCHLUNZEN F, ZARIVACH R, HARMS J, BASHAN A, TOCILJ A, ALBRECHT R et al.: Structural basis for the interaction of antibiotics with the peptidyl transferase centre in eubacteria. Nature (2001) 413:814-821.
47. POEHLSGAARD J, DOUTHWAITE S: The macrolide binding site on the bacterial ribosome. Curr. Drug Targets Infect. Disord. (2002) 2:67-78.
48. TAIT-KAMRADT A, DAVIES T, CRONAN M, JACOBS MR, APPELBAUM PC, SUTCLIFFE J: Mutations in 23S rRNA and ribosomal protein L4 account for resistance in pneumococcal strains selected in vitro by macrolide passage. Antimicrob. Agents Chemother. (2000) 44:2118-2125.
49. HANSEN JL, IPPOLITO JA, BAN N, NISSEN P, MOORE PB, STEITZ TA: The structures of four macrolide antibiotics bound to the large ribosomal subunit. Mol. Cell (2002) 10:117-128.
50. DOUTHWAITE S, CHAMPNEY WS: Structures of ketolides and macrolides determine their mode of interaction with the ribosomal target site. J. Antimicrob. Chemother. (2001) 48(Suppl. T1):1-8.
51. CHAMPNEY WS: Bacterial ribosomal subunit synthesis: a novel antibiotic target. Curr. Drug Targets Infect. Disord. (2001) 1:19-36.
52. SKINNER R, CUNDLIFFE E, SCHMIDT FJ: Site of action of a ribosomal RNA methylase responsible for resistance to erythromycin and other antibiotics. J. Biol. Chem. (1983) 258:12702-12706.
53. ROBERTS MC, SUTCLIFFE, J, COURVALIN P, JENSEN LB, ROOD J, SEPPALA H: Nomenclature for macrolide and macrolide-lincosamide-streptogramin B resistance determinants. Antimicrob. Agents Chemother. (1999) 43:2823-2830.
54. TAKASHIMA H: Structural consideration of macrolide antibiotics in relation to the ribosomal interaction and drug design. Curr. Top. Med. Chem. (2003) 3:991-999.
55. WEISBLUM B: Insights into erythromycin action from studies of its activity as inducer of resistance. Antimicrob. Agents Chemother. (1995) 39:797-805.
56. LECLERCQ R: Mechanisms of resistance to macrolides and lincosamides: nature of the resistance elements and their clinical implications. Clin. Infect. Dis. (2002) 34:482-492.
57. WEISBLUM B: Erythromycin resistance by ribosome modification. Antimicrob. Agents Chemother. (1995) 39:577-585.
58. TAIT-KAMRADT A, DAVIES T, APPELBAUM PC et al.: Two new mechanisms of macrolide resistance in clinical strains of Streptococcus pneumoniae from Eastern Europe and North America. Antimicrob. Agents Chemother. (2000) 44:3395-3401.
59. CANU A, MALBRUNY B, COQUEMONT M, DAVIES TA, APPELBAUM PC, LECLERCQ R: Diversity of ribosomal mutations conferring resistance to macrolides, clindamycin, streptogramin and telithromycin in Streptococcus pneumoniae. Antimicrob. Agents Chemother. (2002) 46:125-131.
60. ZHONG P, SHORTRIDGE VD: The role of efflux in macrolide resistance. Drug Resist. Update (2000) 3:325-329.
61. HOBAN DJ, WIERZBOWSKI AK, NICHOL K, ZHANEL GG: Macrolide-resistant Streptococcus pneumoniae in Canada during 1998-1999: prevalence of mef(A) and erm(B) and susceptibilities to ketolides. Antimicrob. Agents Chemother. (2001) 45:2147-2150.
62. MATSUOKA M, INOUE M, ENDO Y, NAKAJIMA Y: Characteristic expression of three genes, msr(A), mph(C) and erm(Y), that confer resistance to macrolide antibiotics on Staphylococcus aureus. FEMS Microbiol. Lett. (2003) 220:287-293.
63. VERDIER L, GHARBI-BENAROUS J, BERTHO G, MAUVAIS P, GIRAULT JP: Antibiotic resistance peptides: interaction of peptides conferring macrolide and ketolide resistance with Staphylococcus aureus ribosomes: conformation of bound peptides as determined by transferred NOE experiments. Biochemistry (2002) 41:4218-4229.
64. HOBAN DJ, DOERN GV, FLUIT AC, ROUSSEL-DELVALLEZ M, JONES RN: Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin. Infect. Dis. (2001) 32(Suppl. 2):S81-S93.
65. ZHANEL GG, WALTERS M, NOREDDIN A et al.: The ketolides: a critical review. Drugs (2002) 62:1771-1804.
66. NILIUS AM, MA Z: Ketolides: the future of the macrolides? Curr. Opin. Pharmacol. (2002) 2:493-500.
67. BONNEFOY A, GIRARD AM, AGOURIDAS C, CHANTOT JF: Ketolides lack inducibility properties of MLS(B) resistance phenotype. J. Antimicrob. Chemother. (1997) 40:85-90.
68. LECLERCQ R: Safeguarding future antimicrobial options: strategies to minimize resistance. Clin. Microbiol. Infect. (2001) 7(Suppl. 3):18-23.
69. ROSATO A, VICARINI H, BONNEFOY A, CHANTOT JF, LECLERCQ R: A new ketolide, HMR 3004, active against streptococci inducibly resistant to erythromycin. Antimicrob. Agents Chemother. (1998) 42:1392-1396.
70. ZHONG P, CAO Z, HAMMOND R et al.: Induction of ribosome methylation in MLS-resistant Streptococcus pneumoniae by mactolides and ketolides. Microb. Drug Resist. (1999) 5:183-188.
71. EVRARD-TODESCHI N, GHARBI-BENAROUS J, GAILLET C et al.: Conformations in solution and bound to bacterial ribosomes of ketolides, HMR 3647 (telithromycin) and RU 72366: a new class of highly potent antibacterials. Bioorg. Med. Chem. (2000) 8:1579-1597.
72. HANSEN LH, MAUVAIS P, DOUTHWAITE S: The macrolide-ketolide antibiotic binding site is formed by structures in domains II and V of 23S ribosomal RNA. Mol. Microbiol. (1999) 31:623-631.
73. GARZA-RAMOS G, XIONG L, ZHONG P, MANKIN A: Binding site of macrolide antibiotics on the ribosome: new resistance mutation identifies a specific interaction of ketolides with rRNA. J. Bacteriol. (2001) 183:6898-6907.
74. CAPOBIANCO JO, CAO Z, SHORTRIDGE VD, MA Z, FLAMM RK, ZHONG P: Studies of the novel ketolide ABT-773: transport, binding to ribosomes and inhibition of protein synthesis in Streptococcus pneumoniae. Antimicrob. Agents Chemother. (2000) 44:1562-1567.
75. DOUTHWAITE S: Structure-activity relationships of ketolides versus macrolides. Clin. Microbiol. Infect. (2001) 7(Suppl. 3):11-17.
76. ACKERMANN G, RODLOFF AC: Drugs of the 21st century: telithromycin (HMR 3647)-the first ketolide. J. Antimicrob. Chemother. (2003) 51:497-511.
77. SAEZ-NIETO JA, VAZQUEZ JA: In vitro activities of ketolides HMR 3647 and HMR 3004, levofloxacin and other quinolones and macrolides against Neisseria spp. and Moraxella catarrhalis. Antimicrob. Agents Chemother. (1999) 43:983-984.
78. ZHANEL GG, PALATNICK L, NICHOL KA, LOW DE, HOBAN DJ: Antimicrobial resistance in Haemophilus influenzae and Moraxella catarrhalis respiratory tract isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002. Antimicrob. Agents Chemother. (2003) 47:1875-1881.
79. ANDREWS JM, WELLER TM, ASHBY JP, WALKER RM, WISE R: The in vitro activity of ABT773, a new ketolide antimicrobial agent. J. Antimicrob. Chemother. (2000) 46:1017-1022.
80. BIEDENBACH DJ, BARRETT MS, JONES RN: Comparative antimicrobial activity and kill-curve investigations of novel ketolide antimicrobial agents (HMR 3004 and HMR 3647) tested against Haemophilus influenzae and Moraxella catarrhalis strains. Diagn. Microbiol. Infect. Dis. (1998) 31:349-353.
81. BOSWELL FJ, ANDREWS JM, ASHBY JP, FOGARTY C, BRENWALD NP, WISE R: The in vitro activity of HMR 3647, a new ketolide antimicrobial agent. J. Antimicrob. Chemother. (1998) 42:703-709.
82. PANKUCH GA, HOELLMAN DB, LIN G, BAJAKSOUZIAN S, JACOBS MR, APPELBAUM PC: Activity of HMR 3647 compared to those of five agents against Haemophilus influenzae and Moraxella catarrhalis by MIC determination and time-kill assay. Antimicrob. Agents Chemother. (1998) 42:3032-3034.
83. ZHANEL GG, HOBAN DJ: Ketolides in the treatment of respiratory infections. Expert Opin. Pharmacother. (2002) 3:277-297.
84. YAMAGUCHI T, HIRAKATA Y, IZUMIKAWA K et al.: In vitro activity of telithromycin (HMR3647), a new ketolide, against clinical isolates of Mycoplasma pneumoniae in Japan. Antimicrob. Agents Chemother. (2000) 44:1381-1382.
85. BEBEAR CM, RENAUDIN H, BRYSKIER A, BEBEAR C: Comparative activities of telithromycin (HMR 3647), levofloxacin and other antimicrobial agents against human mycoplasmas. Antimicrob. Agents Chemother. (2000) 44:1980-1982.
86. EDELSTEIN PH, EDELSTEIN MA: In vitro activity of the ketolide HMR 3647 (RU 6647) for Legionella spp, its pharmacokinetics in guinea-pigs and use of the drug to treat guinea-pigs with Legionella pneumophila pneumonia. Antimicrob. Agents Chemother. (1999) 43:90-95.
87. SCHULIN T, WENNERSTEN CB, FERRARO MJ, MOELLERING RC JR, ELIOPOULOS GM: Susceptibilities of Legionella spp. to newer antimicrobials in vitro. Antimicrob. Agents Chemother. (1998) 42:1520-1523.
88. ROBLIN PM, HAMMERSCHLAG MR: In vitro activity of a new ketolide antibiotic, HMR 3647, against Chlamydia pneumoniae. Antimicrob. Agents Chemother. (1998) 42:1515-1516.
89. STRIGL S, ROBLIN PM, REZNIK T, HAMMERSCHLAG MR: In vitro activity of ABT-773, a new ketolide antibiotic, against Chlamydia pneumoniae. Antimicrob. Agents Chemother. (2000) 44:1112-1113.
90. MOROSINI MI, CANTON R, LOZA E, DEL CAMPO R, ALMARAZ F, BAQUERO F: Streptococcuspyogenes isolates with characterized macrolide resistance mechanisms in Spain: in vitro activities of telithromycin and cethromycin. J. Antimicrob. Chemother. (2003) 52:50-55.
91. NAGAI K, APPELBAUM PC, DAVIES TA et al.: Susceptibility to telithromycin in 1,011 Streptococcus pyogenes isolates from 10 central and Eastern European countries. Antimicrob. Agents Chemother. (2002) 46:546-549.
92. GIOVANETTI E, MONTANARI MP, MINGOIA M, VARALDO PE: Phenotypes and genotypes of erythromycin-resistant Streptococcuspyogenes strains in Italy and heterogeneity of inducibly resistant strains. Antimicrob. Agents Chemother. (1999) 43:1935-1940.
93. SCHMITZ FJ, PETRIDOU J, MILATOVIC D, VERHOEF J, FLUIT AC, SCHWARZ S: In vitro activity of new ketolides against macrolide-susceptible and -resistant Staphylococcus aureus isolates with defined resistance gene status. J. Antimicrob. Chemother. (2002) 49:580-582.
94. MALATHUM K, COQUE TM, SINGH KV, MURRAY BE: In vitro activities of two ketolides, HMR 3647 and HMR 3004, against Gram-positive bacteria. Amimicrob. Agents Chemother. (1999) 43:930-936.
95. CREDITO KL, LIN G, PANKUCH GA, BAJAKSOUZIAN S, JACOBS MR, APPELBAUM PC: Susceptibilities of Haemophilus influenzae and Moraxella catarrhalis to ABT-773 compared to their susceptibilities to 11 other agents. Antimicrob. Agents Chemother. (2001) 45:67-72.
96. JOHNSON CN, BENJAMIN WH JR, GREY BM, CRAIN MC, EDWARDS KM, WAITES KB: In vitro activity of ABT-773, telithromycin and eight other antimicrobials against eryrhromycin-resistant Streptococcus pneumoniae respiratory isolates of children. Int. J. Antimicrob. Agents (2001) 18:531-535.
97. NILIUS AM, BUI MH, ALMER L et a.: Comparative in vitro activity of ABT-773, a novel antibacterial ketolide. Antimicrob. Agents Chemother. (2001) 45:2163-2168.
98. SINGH KV, MALATHUM K, MURRAY BE: In vitro activities of a new ketolide, ABT-773, against multi-drug resistant Gram-positive cocci. Antimicrob. Agents Chemother. (2001) 45:3640-3643.
99. VON EIFF C, PETERS G: Comparative in vitro activity of ABT-773 and two macrolides against staphylococci. J. Antimicrob. Chemother. (2002) 49:189-192.
100. WAITES KB, CRABB DM, DUFFY LB: In vitro activities of ABT-773 and other antimicrobials against human mycoplasmas. Antimicrob. Agents Chemother. (2003) 47:39-42.
101. MASON EO JR, LAMBERTH LB, KAPLAN SL, GROUP USMPS: Activity of a new ketolide ABT-773 in vitro against S. pneumoniae non-susceptible to penicillin or macrolides (abstract no. 1002). 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; 2001 Sept 22-25; Chicago, USA (2001).
102. NAMOURE F, WESSELS DH, PASCUAL MH, REYNOLDS D, SULTAN E, LENFANT B: Pharmacokinetics of the new ketolide telithromycin (HMR 3647) administered in ascending single and multiple doses. Antimicrob. Agents Chemother. (2001) 45:170-175.
103. EDLUND C, ALVAN G, BARKHOLT L, VACHERON F, NORD CE: Pharmacokinetics and comparative effects of telithromycin (HMR 3647) and clarithromycin on the oropharyngeal and intestinal microflora. J. Antimicrob. Chemother. (2000) 46:741-749.
104. BHARGAVA V, LENFANT B, PERRET C, PASCUAL MH, SULTAN E, MONTAY G: Lack of effect of food on the bioavailability of a new ketolide antibacterial, telithromycin. Scand. J. Infect. Dis. (2002) 34:823-826.
105. PERRET C, LENFANT B, WEINLING E: et al.: Pharmacokinetics and absolute oral bioavailability of an 800-mg oral dose of telithromycin in healthy young and elderly volunteers. Chemotherapy (2002) 48:217-223.
106. NICOLAU DP: Pharmacodynamic rationale for short-duration antibacterial therapy. J. Infect. (2002) 44(Suppl. A):17-23.
107. NAMOUR F, SULTAN E, PASCUAL MH, LENFANT B: Penetration of telithromycin (HMR 3647), a new ketolide antimicrobial, into inflammatory blister fluid following oral administration. J. Antimicrob. Chemother. (2002) 49:1035-1038.
108. BONNEFOY A, LE PRIOL P: Antibacterial activity of telithromycin (HMR 3647) in relation to in vitro simulated human plasma kinetics. J. Antimicrob. Chemother. (2001) 47:471-473.
109. PLUIM J, SULTAN E, LEROY B: Population pharmacokinetics support the convenient once-daily 800 mg dosage of telithromcyin in patients with upper and lower RTIs, including special populations (abstract no. P1263). 11th European Congress of Clinical and Microbiological Infectious Diseases; 2001; Apr 1-4; Istanbul, Turkey (2001).
110. PASCUAL A, BALLESTA S, GARCIA I, PEREA EJ: Uptake and intracellular activity of ketolide HMR 3647 in human phagocytic and non-phagocytic cells. Clin. Microbiol. Infect. (2001) 7:65-69.
111. MIOSSEC-BARTOLI C, PILATRE L, PEYRON P et al.: The new ketolide HMR3647 accumulates in the azurophil granules of human polymorphonuclear cells. Antimicrob. Agents Chemother. (1999) 43:2457-2462.
112. VAZIFEH D, PREIRA A, BRYSKIER A, LABRO MT: Interactions between HMR 3647, a new ketolide and human polymorphonudear neutrophils. Antimicrob. Agents Chemother. (1998) 42:1944-1951.
113. AVENTIS PHARMACEUTICALS: Ketek (telithromycin). Briefing document for the Food and Drug Andministration Anti-Infective Drug Products Advisery Committee meeting. Data on file. Bridgewater, NJ. March 2001.
114. BALFOUR JA, FIGGITT DP: Telithromycin. Drugs (2001) 61:815-29; discussion 830-831.
115. BEARDEN DT, NEUHAUSER MM, GAREY KW. Telithromycin: an oral ketolide for respiratory infections. Pharmacotherapy (2001) 21:1204-1222.
116. SHAIN CS, AMSDEN GW: Telithromycin: the first of the ketolides. Ann. Pharmacother. (2002) 36:452-464.
117. DEMOLIS JL, VACHERON F, CARDUS S, FUNCK-BRENTANO C: Effect of single and repeated oral doses of telithromycin on cardiac QT interval in healthy subjects. Clin. Pharmacol. Ther. (2003) 73:242-252.
118. BHARGAVA V, LEROY B, SHI J, MONTAY G: Effect of telithromycin on the pharmacokinetics of theophylline in healthy volunteers (abstract no. 1832). 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2002 Sept 27-30; San Diego, USA (2002).
119. SHI J, MONTAY G, LEROY B, BHARGAVA V: Effects of ketoconazole and itraconazole on the pharmacokinetics of telithromycin, a new ketolide antibiotic (abstract no. 1833). 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2002 Sept 27-30; San Diego, USA (2002).
120. MONTAY G, SHI J, LEROY B, BHARGAVA V: Effects of telithromycin on the pharmacokinetics of digoxin in healthy men (abstract no. 1834). 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2002 Sept 27-30; San Diego, USA (2002).
121. MUNCKHOF WJ, BORLACE G, TURNIDGE JD: Postantibiotic suppression of growth of erythromycin A-susceptible and -resistant gram-positive bacteria by the ketolides telithromycin (HMR 3647) and HMR 3004. Antimicrob. Agents Chemother. (2000) 44(6):1749-1753.
122. DUBOIS J, ST-PIERRE C: Postantibiotic effect (PAE) and bactericidal activity of HMR 3647 and other antimicrobial agents against respiratory pathogens (abstract no. 1242). 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1999 Sept 26-29; San Francisco, USA (1999).
123. BONNEFOY A, GUITTON M, DELACHAUME C, LE PRIOL R, GIRARD AM: In vivo efficacy of the new ketolide telithromycin (HMR 3647) in murine infection models. Antimicrob. Agents Chemother. (2001) 45:1688-1692.
124. MATTOES HM, TESSIER PR, NIGHTINGALE CH, NICOLAU DP: Bactericidal activity of telithromycin against macrolide resistant ((ermB), mef(A)) and fluoroquinolone-resistant Streptococcus pneumoniae in a murine thigh infection model (abstract no. 1656). 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; 2001 Sept 22-25; Chicago, USA; American Society for Microbiology; Washington, DC, USA (2001).
125. PIPER KE, ROUSE MS, STECKELBERG JM, WILSON WR, PATEL R: Ketolide treatment of Haemophilus influenzae experimental pneumonia. Antimicrob. Agents Chemother. (1999) 43:708-710.
126. FOGARTY C, PATEL T, GALBRAITH H, ZUBERBUHLER G, LEROY B: Efficacy of the first ketolide antibacterial, telithromycin, in the treatment of community-acquired pneumonia caused by Streptococcus pneumoniae (abstract no. 857). 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; 2001 Sept 22-25; Chicago, USA (2001).
127. CARBON C, MOOLA S, VELANCSICS I, LEROY B, MANICKAM R, DECOSTA P: Efficacy of telithromycin (HMR 3647), a new once-daily antimicrobial, in the treatment of community-acquired pneumonia (abstract no. 2245). 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sept 17-20; Toronto, Canada (2000).
128. VAN RENSBURG DJ, MATTHEWS PA, LEROY B: Efficacy and safety of telithromycin in community-acquired pneumonia. Curr. Med. Res. Opin. (2002) 18:397-400.
129. PULLMAN J, BOUCHER P, LAVIN B, PATEL M: Clinical and bacteriological efficacy of telithromycin versus clarithromycin in patients with community-acquired pneumonia due to Streptococcus pneumoniae, including erythromycin-resistant strains (abstract no. 372). 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; 2001 Sept 22-25; Chicago, USA (2001).
130. HAGBERG L, TORRES A, VAN RENSBURG D, LEROY B, RANGARAJU M, RUUTH E: Efficacy and tolerability of once-daily telithromycin compared with high-dose amoxicillin for treatment of community-acquired pneumonia. Infection (2002) 30:378-386.
131. TELLIER G, HASSMAN J, LEROY B, SIDAROUS E, YOUNGBLOOD D: Oral telithromycin (HMR 3647) 800 mg once daily is well-tolerated and as effective as oral clarithromycin 500 mg twice daily in community-acquired pneumonia (CAP) in adults (abstract no. 2227). 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sept 17-20, Toronto, Canada (2000).
132. TELLIER G, LASKO B, LEROY B, SIDAROUS E, ANDRADE C: Oral telithromycin (HMR 3647) 800 mg once daily for 5 days and 10 days is well-tolerated and as effective as amoxicillin/clavulanic acid 500/125 mg three-times daily for 10 days in acute maxillary sinusitis (AMS) in adults (abstract no. 2226). 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sept 17-20, Toronto, Canada (2000).
133. AUBIER M, ALDONS PM, LEAK et al.: Telithromycin is as effective as amoxicillin/clavulanate in acute exacerbations of chronic bronchitis. Respir. Med. (2002) 96:862-871.
134. DEABATE C, HEYDER A, LEROY B: Oral telithromycin (HMR 3647) 800 mg once daily for 5 days is well-tolerated and as effective as cefuroxime axetil 500 mg twice daily for 10 days in adults with acute exacerbations of chronic bronchitis (AECB) (abstract no. 2228). 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sept 17-20; Toronto, Canada (2000).
135. CHANG J, STEWART J, BRUMPT I: Telithromycin treatment of CAP is associated with lower usage of additional RTI-related antibiotics than high-dose amoxycillin in a randomised, double-blind, cooparative trial (abstract no. P418). 11th European Congress of Clinical Microbiology and Infectious Diseases; 2001 Apr 1-4; Istanbul, Turkey (2001).
136. NORRBY S, RABIE W, BACART P et al.: Efficacy of 5 days' telithromycin (HMR 3647) versus 10 days' penicillin V in the treatment of pharyngitis in adults (abstract no. 2242). 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sept 17-20; Toronto, Canada (2000).
137. QUINN J, RUOFF GE, ZITER PS: Efficacy and tolerability of 5-day, once-daily telithromycin compared with 10-day, twice-daily clarithromycin for the treatment of group A beta-hemolytic streptococcal tonsillitis/pharyngitis: a multicenter, randomized, double-blind, parallel-group study. Clin. Ther. (2003) 25:422-443.
138. ROOS K, BRUNSWIG-PITSCHNER C, KOSTRICA R et al.: Efficacy and tolerability of a 5-day course of a new ketolide antimicrobial, telithromycin (HMR 3647), for the treatment of acute sinusitis (abstract no. 2243). 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sept 17-20; Toronto, Canada (2000).
139. FOGARTY CM, KOHNO S, BUCHANAN P, AUBIER M, BAZ M: Community-acquired respiratory tract infections caused by resistant pneumococci: clinical and bacteriological efficacy of the ketolide telithromycin. J. Antimicrob. Chemother. (2003) 51:947-955.
140. BUCHANAN P, MCNEIL D, TADY D, ANDRADE C, LEROY B: A 5 day course of telithromycin the first ketolide antibacterial is as effective as 10 days cefuoxime axetil in the treatment of acute maxillary sinusitis (abstract no. 910). 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; 2001 Sept 22-25; Chicago, USA (2001).
141. LORENZ J: Clinical efficacy of new antibacterial therapies in at-risk populations. J. Infect. (2002) 44(Suppl. A):25-30.
142. OR YS, CLARK RF, WANG S et al.: Design, synthesis and antimicrobial activity of 6-O-substituted ketolides active against resistant respiratory tract pathogens. J. Med. Chem. (2000) 43:1045-1049.
143. CAPOBIANCO J, SHORTRIDGE V, MA Z, PHAN L, ZHONG P: Rapid drug accumulation of ABT-773 in Streptococcus pneumoniae (abstract no 2136). 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1999 Sept 26-29; San Francisco, USA (1999).
144. PRADHAN R, GUSTAVSON L, LONDO D, ZHANG Y, ZHANG J, PARIS M: Single oral dose pharmacokinetics and safety of ABT-773 in healthy subjects (abstract no. 2135). 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sept 17-20; Toronto, Canada (2000).
145. PRADHAN R, GUSTAVSON L, LONDO D, ZHANG Y, ZHANG J, PARIS M: The bioavailability of ABT-773 is unaffected by food (abstract no. 2138). 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sept 17-20; Toronto, Canada (2000).
146. GARCIA I, PASCUAL A, BALLESTA S, DEL CASTILLO C, PEREA EJ: Accumulation and activity of cethromycin (ABT-773) within human polymorphonuclear leucocytes. J. Antimicrob. Chemother. (2003) 52:24-28.
147. PASCUAL A, GARCIA I, DEL CASTILLO C, BALLESTA S, PEREA EJ: Intracellular penetration and activity of ABT-773 in human polymorphonuclear leukocytes (abstract no. 485). 42nd ICAAC Abstracts, American Society for Microbiology,
148. JUNG R, DANZIGER LH, PENDLAND SL: Intracellular activity of ABT-773 and other antimicrobial agents against Legionella pneumophila. J. Antimicrob. Chemother. (2002) 49:857-861.
149. PENDLAND SL, NEUHAUSER MM, PRAUSE JL: In vitro bactericidal activity of ABT-773 and amoxicillin against erythromycin-susceptible and -resistant strains of Streptococcus pyogenes. J. Antimicrob. Chemother. (2002) 49:671-674.
150. NEUHAUSER MM, JUNG R, DANZIGER LH, PENDLAND SL: In vitro bactericidal activity of ABT-773 versus four other agents against Streptococcus pneumoniae and Haemophilus influenzae. Int. J. Antimicrob. Agents (2002) 20:395-398.
151. DAVIES TA, EDNIE LM, HOELLMAN DM, PANKUCH GA, JACOBS MR, APPELBAUM PC: Antipneumococcal activity of ABT-773 compared to those of 10 other agents. Antimicrob. Agents Chemother. (2000) 44:1894-1899.
152. NEUHAUSER MM, PRAUSE JL, DANZIGER LH, PENDLAND SL: In vitro bactericidal activities of ABT-773 against ermB strains of Streptococcus pneumoniae. Antimicrob. Agents Chemother. (2003) 47:1132-1134.
153. DUBOIS J, ST-PIERRE C: Intracellular activity and postantibiotic effect of ABT-773 against Legionella (abstract no. 2.33). 5th International Conference on the Macrolides, Azalides, Streptogramins, Ketolides and Oxazolidinones; 2000 Jan 26-28; Seville, Spain (2000).
154. CAO Z, RUAN X, MERTA P et al.: Tight ribosome binding, prolonged molecular PAE of ketolide ABT-773 in Haemophilus influenzae (abstract no. 2187). 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2002 Sept 27-30; San Diego, USA (2002).
155. FUJIKAWA T, MIYAZAKI S, ISHII Y et al.: The in vivo activities of ABT-773 in mouse models of respiratory tract infection due to Streptococcus pneumoniae and Haemophilus influenzae (abstract no. 993). 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2002 Sept 27-30; San Diego, USA (2002).
156. MITTEN MJ, MEULBROEK J, NUKKALA M et al.: Efficacies of ABT-773, a new ketolide, against experimental bacterial infections. Antimicrob. Agents Chemother. (2001) 45:2585-2593.
157. MEULBROEK J, MITTEN M, MOLLISON K: Efficacies of ABT-773 and azithromycin against experimental rat lung infections caused by Streptococcus pneumoniaeI (Abstract 2151). 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; 26-29 September 1999; San Francisco, USA (1999).
158. AZOULAY-DUPUIS E, BEDOS J, MOINE P et al.: Efficacy of ABT-773 (ABT), a new ketolide, versus erythromycin (Ery) against penicillin (Peni)/ery sensitive and macrolide resistant Streptococcus pneumoniae (Sp) in a mouse murine model (abstract no. 1018). 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sept 17-20; Toronto, Canada (2000).
159. CAPITANO B, MAGLIO D, BANEVICIUS M, NIGHTINGALE CH, NICOLAU DP: Bactericidal effect of cethromycin (ABT-773) in an immunocompetent murine pneumococcal pneumonia model (abstract no. 1271). 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2002 Sept 27-30; San Diego, USA (2002).
160. MICHELOW I, HARDY R, OLSEN K et al.: Effectiveness of ABT-773 in an experimental model of multi-drug resistant (MDR) Streptococcus pneumoniae (Sp) bacteremic pneumonia (abstract no. 986). 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2002 Sept 27-30; San Diego, USA (2002).
161. KIM MK, ZHOU W, TESSIER PR et al.: Bactericidal effect and pharmacodynamics of cethromycin (ABT-773) in a murine pneumococcal pneumonia model. Antimicrob. Agents Chemother. (2002) 46:3185-3192.
162. RIOS A, HARDY R, MEJIAS A et al.: ABT-773 for the treatment of experimental Mycoplasma pneumoniae pneumonia (asbstract no. 697). 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2002 Sept 27-30; San Diego, USA (2002).
163. HAMMERSCHLAG MR, REZNIK T, ROBLIN PM, RAMIREZ J, SUMMERSGILL J, BUKOFZER S: Microbiological efficacy of ABT-773 (cethromycin) for the treatment of community-acquired pneumonia due to Chlamydia pneumoniae. J. Antimicrob. Chemother. (2003) 51:1025-1028.
164. GUSTAVSON L, YE X, BEASON J et al.: ABT-773 has no clinically-important effect on the pharmacokinetics and safety of theophylline (abstract no. 941). 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2002 Sept 27-30; San Diego, USA (2002).
165. PLETZ MW, PREECHACHATCHAVAL V, BULITTA J, ALLEWELT M, BURKHARDT O, LODE H: ABT-773: pharmacokinetics and interactions with ranitidine and sucralfate. Antimicrob. Agents Chemother. (2003) 47:1129-1131.
166. MA Z, FLORJANCIC AS: HMR-3562. Aventis Pharma. Curr. Opin. Investig. Drugs (2001) 2:1702-1705.
167. DENIS A, BRETIN F, FROMENTIN C et al.: Beta-keto-ester chemistry and ketolides. Synthesis and antibacterial activity of 2-halogeno, 2-methyl and 2,3 enol-ether ketolides. Bioorg. Med. Chem. Lett. (2000) 10:2019-2022.
168. NAGAI K, DAVIES TA, EDNIE LM et al.: Activities of a new fluoroketolide, HMR 3787 and its (des)-fluor derivative RU 64399 compared to those of telithromycin erythromycin A, azithromycin, clarithromycin and clindamycin against macrolide-susceptible or -resistant Streptococcus pneumoniae and S. pyogenes. Antimicrob. Agents Chemother. (2001) 45:3242-3245.
169. BOZDOGAN B, CLARK C, BRYSKIER A, JACOBS MR, APPELBAUM PC: Activities of HMR 3787 and RU 64399 compared with those of four other agents against Haemophilus influenzae and Haemophilus parainfluenzae. Antimicrob. Agents Chemother. (2003) 47:405-407.
170. GUITTON M, DELACHAUME C, LE PRIOL P, STEIER V, BONNEFOY A: In vitro and in vivo efficacy of a novel fluoro-ketolide HMR 3562 against enterococci. J. Antimicrob. Chemother. (2001) 48:131-135.
171. DELACHAUME C, BONNEFOY A: Efficacy of HMR 3562, a 2-fluoro ketolide, against enterococci in murine hematogenous pyelonephritis (abstract no. 1659). 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2002 Sept 27-30; San Diego, USA (2002).
172. ABDELGHAFFAR H, VAZIFEH D, LABRO MT: Cellular uptake of two fluoroketolides, HMR 3562 and HMR 3787, by human polymorphonuclear neutrophils in vitro. Antimicrob. Agents Chemother. (2001) 45:2798-2806.
173. KASHIMURA M, ASAKA T, MISAWA Y, MATSUMOTO K, MORIMOTO S: Synthesis and antibacterial activity of the tricyclic ketolides TE-802 and its analogs. J. Antibiot. (Tokyo) (2001) 54:664-678.
174. ASAKA T, MANAKA A, SUGIYAMA H: Recent developments in macrolide antimicrobial research. Curr. Top. Med. Chem (2003) 3:961-989.
175. DENIS A, PEJAC JM, BRETIN F, BONNEFOY A: Synthesis of 9-oxime-11,12-carbamate ketolides Through a novel N-deamination reaction of 11,12-hydrazonocarbamate ketolide. Bioorg. Med. Chem. (2003) 11:2389-2394.
176. ABBANAT D, WEBB G, ASHLEY G et al.: In vitro antibacterial activities of naphthyridine-containing ketolides (abstract no. 1663). 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2002 Sept 27-30; San Diego, USA (2002).
177. KEYES RF, CARTER JJ, ENGLUND EE et al.: Synthesis and antibacterial activity of 6-O-arylbutynyl ketolides with improved activity against some key erythromycin-resistant pathogens. J. Med. Chem. (2003) 46:1795-1798.
178. GILL C, ABRUZZO GK, FLATTERY AM et al.: In vivo evaluation of three acid-stable azalide compounds, L-701,677, L-708,299 and L-708,365 compared to erythromycin, azithromycin and clarithromycin. J. Antibiot. (Tokyo) (1995) 48(10):1141-1147.
179. CREEMER LC, TOTH JE, KIRST HA: Synthesis and in vitro antimicrobial activity of 3-keto 16-membered macrolides derived from tylosin. J. Antibiot. (Tokyo) (2002) 55:427-436.
180. LECLERCQ R: Overcoming antimicrobial resistance: profile of a new ketolide antibacterial, telithromycin. J. Antimicrob. Chemother. (2001) 48(Suppl. T1):9-23.
181. TRACZEWSKI M, BROWN S, BARRY A. Susceptibility to telithromycin (HMR 3647) and erythromycin among clinical isolates of Gram-positive pathogens and reassessment of disk diffusion test criteria (abstract no. 2.08). 5th International Conference on the Macrolides, Azalides, Streptogramins, Ketolides and Oxazolidinones. 2000 Jan 26-28; Seville, Spain (2000).
182. DAVIES T, DEWASSE B, JACOBS MR, APPELBAUM PC: In vitro development of resistance to telithromycin (HMR 3647), four macrolides, clindamycin and pristinamycin in Streptococcus pneumoniae. Antimicrob. Agents Chemother. (2000) 44:414-417.
183. NILIUS AM, HENSEY-RUDLOFF DM, REIMANN MA, FLAMM RK: Comparison of selection for mutants with reduced susceptibility to ABT-773, erythromycin and rifampicin in respiratory tract pathogens. J. Antimicrob. Chemother. (2002) 49:831-836.
184. LECLERCQ R: Will resistance to ketolides develop in Streptococcus pneumoniae? J. Infect. (2002) 44(Suppl. A): 11-16.